Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of oral HRS-5346 in adults at high cardiovascular risk with elevated lipoprotein(a)
CTR20263144Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-7262 in dyslipidemia, lipoprotein(a) hyperlipoproteinemia (Lp(a)), cardiac morbidity, sponsored by Shandong Sende. Started Aug 2026; status: active.
02
Drugs
MK-7262
03
Conditions
dyslipidemialipoprotein(a) hyperlipoproteinemia (Lp(a))cardiac morbidity
Beyond the preview
Go deeper on CTR20263144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263144.